ARMR Sciences Inc., a biodefense technology company, has completed a private placement financing with strategic and institutional investors to advance its fentanyl vaccine toward human trials. The placement was led by Joseph Gunnar & Co., LLC, acting as placement agent. The vaccine, backed by the U.S. Department of Defense, is designed to prevent fatal overdoses and address threats from substances such as fentanyl, supporting continued development and clinical progression.
The company is pioneering the first long-acting, preventive immunotherapy to stop synthetic drug overdose before it begins, starting with fentanyl, which is the number one killer of U.S. adults aged 18 to 45. This represents a critical shift in national strategy: from reacting to overdoses to preventing them at the source. According to the company, qualified prospective investors who meet the qualifications of an “accredited investor” can invest $5,000 in this offering and become a shareholder.
For more information, visit the announcement at https://ibn.fm/t39w2.
ARMR Sciences is America’s biodefense technology company, developing next-generation countermeasures against synthetic drug threats such as fentanyl. Through its foundational license, ARMR is backed by early-stage research funding from the U.S. Department of Defense. The company aims to prevent overdoses before they occur, marking a strategic departure from current reactive measures.
The fentanyl crisis has reached alarming levels, with fentanyl being the leading cause of death for adults aged 18 to 45 in the United States. A vaccine that could prevent overdoses would have significant implications for public health, potentially saving thousands of lives each year and reducing the burden on healthcare systems. It also represents a new approach to combating the opioid epidemic, focusing on prevention rather than treatment after the fact.
For more information about ARMR Sciences, visit https://armrsciences.com/.
This development is part of a broader effort to address synthetic drug threats through innovative biotechnology solutions. The successful advancement of this vaccine could pave the way for similar preventive immunotherapies against other dangerous substances.
